Safety and clinical activity of adenosine A2a receptor (A2aR) antagonist, CPI-444, in anti-PD1/PDL1 treatment-refractory renal cell (RCC) and non-small cell lung cancer (NSCLC) patients Meeting Abstract
| Authors: | Fong, L.; Forde, P. M.; Powderly, J. D.; Goldman, J. W.; Nemunaitis, J. J.; Luke, J. J.; Hellmann, M. D.; Kummar, S.; Doebele, R. C.; Mahadevan, D.; Gadgeel, S. M.; Hughes, B. G. M.; Markman, B.; Riese, M. J.; Brody, J.; Emens, L. A.; McCaffery, I.; Miller, R. A.; Laport, G. |
| Abstract Title: | Safety and clinical activity of adenosine A2a receptor (A2aR) antagonist, CPI-444, in anti-PD1/PDL1 treatment-refractory renal cell (RCC) and non-small cell lung cancer (NSCLC) patients |
| Meeting Title: | 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 35 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2017 Jun 2-6 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2017-05-20 |
| Start Page: | 139s |
| Language: | English |
| ACCESSION: | WOS:000411895705134 |
| DOI: | 10.1200/JCO.2017.35.15_suppl.3004 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 3004 -- Source: Wos |
